Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma

Blood

Volumn 114, Issue 24, 2009, Pages 5007-50515

  Li, Bohua ^a,b   Zhao, Lei ^a   Guo, Huaizu ^c   Wang, Chong ^c   Zhang, Xunming ^a   Wu, Lan ^a   Chen, Lin ^a   Tong, Qing ^a   Qian, Weizhu ^a,b   Wang, Hao ^a,b   Guo, Yajun ^a,b,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b National Engineering Research Center for Antibody Medicine   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CD20 ANTIBODY; MONOCLONAL ANTIBODY; RITUXIMAB; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; LYMPHOMA CELL; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; ANIMAL; ANTIBODY AFFINITY; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENETICS; MOUSE MUTANT; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COMPLEMENTARITY DETERMINING REGIONS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, SCID; POINT MUTATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 73949084380     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-06-225474     Document Type: Article

References (47)

1. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 1988;7(3):711-717.
2. Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol. 1993;121(5):1121-1132.
3. Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J Lab Clin Med. 1999;134(5):445-450.
4. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44(16):3823-3837.
5. Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology. 2007;2007(1):233-242.
6. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med. 2008;359(6):613-626.
7. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104(9):2635-2642.
8. Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101(3):1045-1052.
9. Chan HTC, Hughes D, French RR, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into Triton X-100 insoluble membrane rafts. Cancer Res. 2003;63(17):5480-5489.
10. Mathas S, Rickers A, Bommert K, Dorken B, Mapara MY. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res. 2000;60(24):7170-7176.
11. Marignani M, Angeletti S, delle FG. Monoclonal antibody therapy and non-Hodgkin's lymphoma. N Engl J Med. 2009;360(2):192-193.
12. Weng W, Stavenhagen J, Koenig S, Levy R. Rituximab variants with re-engineered Fc with higher affinity to activating Fcγ R eliminate the functional difference between Fcγ R genotypes [abstract]. Blood. 2005;106(11):105.
13. Bowles JA, Wang S, Link BK, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood. 2006;108(8):2648-2654.
14. Goldenberg DM, Rossi EA, Stein R, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood. 2009;113(5):1062-1070.
15. Umana P, Moessner E, Bruenker P, et al. Novel 3rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction. Session type: oral session [abstract]. Blood. 2006;108(11):229.
16. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104(6):1793-1800.
17. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177(1):362-371.
18. Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes: heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood. 2002;99(9):3256-3262.
19. Perosa F, Favoino E, Caragnano MA, Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood. 2006;107(3):1070-1077.
20. Perosa F, Favoino E, Vicenti C, et al. Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes. J Immunol. 2009;182(1):416-423.
21. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103(7):2738-2743.
22. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother. 2000;48(12):673-683.
23. Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res. 2007;67(3):1270-1281.
24. Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008;14(5):1561-1570.
25. Du J, Wang H, Zhong C, et al. Structural basis for recognition of CD20 by therapeutic antibody rituximab. J Biol Chem. 2007;282(20):15073-15080.
26. Gemma S, Gabellieri E, Huleatt P, et al. Discovery of huperzine A-tacrine hybrids as potent inhibitors of human cholinesterases targeting their midgorge recognition sites. J Med Chem. 2006;49(11):3421-3425.
27. Savini L, Gaeta A, Fattorusso C, et al. Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites: rational design of novel, selective, and highly potent cholinesterase inhibitors. J Med Chem. 2003;46(1):1-4.
28. Dauber-Osguthorpe P, Roberts VA, Osguthorpe DJ, Wolff J, Genest M, Hagler AT. Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase-trimethoprim, a drug-receptor system. Proteins. 1988;4(1):31-47.
29. Bernard RB, Robert EB, Barry DO, David JS, Swaminathan S, Martin K. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem. 1983;4(2):187-217.
30. Im W, Lee MS, Brooks CR. Generalized born model with a simple smoothing function. J Comput Chem. 2003;24(14):1691-1702.
31. Kollman PA, Massova I, Reyes C, et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res. 2000;33(12):889-897.
32. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435-445.
33. Li B, Shi S, Qian W, et al. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res. 2008;68(7):2400-2408.
34. Xiao Y, Meyer EL, Thompson JM, Surin A, Wroblewski J, Kellar KJ. Rat alpha 3/beta 4 subtype of neuronal nicotinic acetylcholine receptor stably expressed in a transfected cell line: pharmacology of ligand binding and function. Mol Pharmacol. 1998;54(2):322-333.
35. Selzer T, Albeck S, Schreiber G. Rational design of faster associating and tighter binding protein complexes. Nat Struct Biol. 2000;7(7):537-541.
36. Marvin JS, Lowman HB. Redesigning an antibody fragment for faster association with its antigen. Biochemistry. 2003;42(23):7077-7083.
37. Walshe CA, Beers SA, French RR, et al. Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling. J Biol Chem. 2008;283(25):16971-16984.
38. Bland JM, Altman DG. Survival probabilities (the Kaplan-Meier method). BMJ. 1998;317(7172):1572.
39. Du J, Wang H, Zhong C, et al. Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide. Mol Immunol. 2008;45(10):2861-2868.
40. Bonavida B. Rituximab-induced inhibition of anti-apoptotic cell survival pathways: implications in chemoimmunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene. 26(25):3629-3636.
41. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene. 2005;24(13):2121-2143.
42. Davis TA, Kaminski MS, Leonard JP, et al. Results of a randomized study of Bexxar (Tositumomab and I 131 Tositumomab) vs unlabeled Tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma [abstract]. Blood. 2001;98[suppl 1]:843.
43. Beers SA, Chan CH, James S, et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood. 2008;112(10):4170-4177.
44. Vermeulen K, Bockstaele DR, Berneman ZN. Apoptosis: mechanisms and relevance in cancer. Ann Hematol. 2005;84(10):627-639.
45. Broker LE, Kruyt FA, Giaccone G. Cell death independent of caspases: a review. Clin Cancer Res. 2005;11(9):3155-3162.
46. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359-7368.
47. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002;29(suppl 2):2-9.